Results 21 to 30 of about 6,039,132 (349)

Digital Twins for Multiple Sclerosis

Frontiers in Immunology, 2021
An individualized innovative disease management is of great importance for people with multiple sclerosis (pwMS) to cope with the complexity of this chronic, multidimensional disease.
Isabel Voigt, Hernan Inojosa, Anja Dillenseger, Rocco Haase, K. Akgün, T. Ziemssen   +5 more
semanticscholar   +1 more source

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Therapeutic Advances in Neurological Disorders, 2021
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage.
H. Wiendl, R. Gold, T. Berger, T. Derfuss, R. Linker, M. Mäurer, O. Aktas, K. Baum, M. Berghoff, S. Bittner, A. Chan, A. Czapliński, F. Deisenhammer, Franziska Di Pauli, R. D. Du Pasquier, C. Enzinger, E. Fertl, A. Gass, K. Gehring, C. Gobbi, N. Goebels, M. Guger, A. Haghikia, H. Hartung, F. Heidenreich, O. Hoffmann, B. Kallmann, C. Kleinschnitz, L. Klotz, V. Leussink, F. Leutmezer, V. Limmroth, J. Lünemann, A. Lutterotti, S. Meuth, U. Meyding-Lamadé, M. Plattén, P. Rieckmann, S. Schmidt, H. Tumani, F. Weber, Martin S. Weber, U. Zettl, T. Ziemssen, F. Zipp   +44 more
semanticscholar   +1 more source

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis

Vaccines, 2023
Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug Administration (FDA) in the United States and have proven effective for the prevention of morbidity and death from COVID-19.
Luke B. Elias, Aliya Jaber, Margarita Manzano, Mark Leekoff, Andrew Sylvester, Matthew A. Tremblay   +5 more
doaj   +1 more source

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]

Neurology and Therapy, 2023
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no ...
Scott D. Newsome, Cherie Binns, Ulrike W. Kaunzner, Seth Morgan, June Halper   +4 more
doaj   +1 more source

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

New England Journal of Medicine, 2020
BACKGROUND Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation.
S. Hauser, A. Bar-Or, Jeffrey A. Cohen, G. Comi, J. Correale, P. Coyle, A. Cross, J. de Seze, D. Leppert, X. Montalban, K. Selmaj, H. Wiendl, Cécile Kerloeguen, R. Willi, Bingbing Li, A. Kakarieka, Davorka Tomic, A. Goodyear, Ratnakar Pingili, D. Häring, K. Ramanathan, M. Merschhemke, L. Kappos   +22 more
semanticscholar   +1 more source

Multiple Sclerosis and Schizophrenia [PDF]

International Journal of Molecular Sciences, 2017
The psychiatric and neurological aspects of health may present methodological challenges in the diagnosis and treatment of disease. This is especially true for patients whose symptoms indicate the coexistence of multiple sclerosis (MS) and schizophrenia (SCZ).
Arneth, Borros M, Justus Liebig University Giessen   +1 more
openaire   +6 more sources

Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis

Nature Communications, 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
International Multiple Sclerosis Genetics Consortium
doaj   +1 more source

Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity

Journal of Patient Experience, 2021
Pediatric new drug trials are federally mandated, but family perspectives in multiple sclerosis (MS) research are limited. Due to MS chronicity and long-term medical system involvement, we obtained family views on research priorities and optimized ...
Leslie A Mandel PhD, MA, MS, Ellen O’Donnell PhD, Katia Canenguez PhD, EdM, Paola B Castro-Mendoza BSc, MSc, Tim Lotze MD, Emmanuelle Waubant MD, PhD, Bianca Weinstock-Guttmann MD, Tanuja Chitnis MD   +7 more
doaj   +1 more source

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

JAMA Neurology, 2020
Key Points Question What are the relative contributions of progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) to overall accumulating disability in patients with relapsing multiple sclerosis?
L. Kappos, J. Wolinsky, G. Giovannoni, D. Arnold, Qing Wang, C. Bernasconi, F. Model, H. Koendgen, M. Manfrini, S. Belachew, S. Hauser   +10 more
semanticscholar   +1 more source

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study

Frontiers in Neurology, 2023
BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses.
Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto   +7 more
doaj   +1 more source